[Prospective, multicentric, open, and controlled evaluation of the effectiveness of prostatron 2.5 in the treatment of prostatic benign hypertrophy: 1-year results].
OBJECTIVE
Evaluation of the efficacy at 1 year of the Prostatron 2.5 in the treatment of BPH weighing more than 40 grams.


METHODS
46 patients over the age of 50 years presenting with BPH > 40 grams responsible for a maximum flow rate (MFR) < 9 ml/s and a mean IPSS score of 18 were prospectively included without randomization, by 5 French Urological Centres. These patients were reviewed at 3, 6 and 12 months. Primary endpoint: MFR; secondary endpoints: Madsen score and IPSS.


RESULTS
No major complications were observed. The mean postoperative catheterization time was 10 days, causing discomfort with a mean score of 5 on a visual analogue scale from 0 to 10.. Maximum flow rate waas 13.4 ML/s at 3 months, 13.4 ml/s at 6 months and 14.7 ml/s at 12 months. The IPSS was improved by 75%.


CONCLUSIONS
Treatment by Prostatron 2.5 improves the MFR and the patient's quality of life, which is maintained for at least 1 year after treatment.
Gattegno
B
B
Service d'Urologie, Hôpital Tenon, Paris, France. bernard.gattegno@tnn.ap-hop-paris.fr
Ciofu
C
C
Flahaut
A
A
Chartier-Kastler
E
E
Desgrandchamps
F
F
Martin
X
X
Vallancien
G
G
Teillac
P
P
Richard
F
F
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000628:therapy*; D013997:Time Factors
Evaluation prospective, multicentrique, ouverte et contrôlée de l'efficacité du Prostatron 2.5 dans le traitement de l'hypertrophie bénigne de la prostate: résultats à 1 an.